Recently, Bristol-Myers Squibb Co. (BMY) received approval from the U.S. Food and Drug Administration (FDA) to market Abilify (aripiprazole) for the treatment of irritability in pediatric patients having autistic disorder. Abilify can be used to treat children aged 6 to 17 years for symptoms of aggression toward others, deliberate self injury, temper tantrums and quick mood swings.  Bristol-Myers and Otsuka Pharmaceutical Co. jointly develop and distribute the drug in the U.S. and Europe. The FDA approval of Abilify for treating irritation in pediatric patients with autistic disorder is based on data from two eight-week late-stage studies in which Abilify significantly improved scores on the irritability subscale of the caregiver-rated Aberrant Behavior Checklist (ABC-I), compared to placebo.  The most common adverse affects were sedation, fatigue, vomiting, somnolence, tremor and pyrexia. However, the efficacy of Abilify for the maintenance treatment of irritability associated with autistic disorder was not ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Wednesday September 30, 2009

DrStockPick.com Stock Report!

COV, PWRM, MSFT, CSRH, NKE, CVAT, ABT

**************************************************************

COV, Covidien plc

COV engages in the development, manufacture, and sale of healthcare products for use in clinical and home settings worldwide. The company operates through four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products, and Medical Supplies.

COV said Wednesday it received Food and Drug Administration clearance for its new endotracheal tube, a device that helps patients breathe.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the

...

Alexza Pharmaceuticals, Inc. announced a private placement equity offering of 8.1 million shares of common stock to several qualified institutional investors. The company will receive $2.4325 per share, or approximately $19.1 million in net proceeds.

Alexza Pharmaceuticals also issued 7.3 million warrants as part of the deal. The warrants entitle the holder to purchase 0.9 shares of common stock at $2.77 per share. The warrants expire in seven years.

Alexza Pharmaceuticals is developing a proprietary drug delivery technology called the Staccato® system. This technology vaporizes unformulated pharmaceutical drugs into an aerosol form that allows rapid systemic delivery through lung inhalation.

Alexza Pharmaceuticals has completed Phase 3 trials for using this technology to deliver Loxapine for use in treating schizophrenic or bipolar disorder patients. The company plans a new drug application submission in 2010.

Staccato® is also being tested for use in other areas, including the treatment

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday September 28, 2009

DrStockPick.com Stock Report!

XRX, PWRM, ABT, CSRH, CMCSA, CVAT, FMCN

**************************************************************

XRX, Xerox Corp.

XRX engages in the development, manufacture, marketing, servicing, and financing of document equipment, software, solutions, and services worldwide.

XRX said Monday it will buy Affiliated Computer Services Inc. for $6.4 billion in cash and stock to create a $22 billion business that combines XRX’s copiers, printers and document management services with the “business process outsourcing” of Dallas-based ACS., joining the expensive race among technology companies to broaden their offerings.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Friday August 28, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE ) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases, has secured the

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Thursday August 27, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE ) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases, has secured the

...

Las Vegas CRWENewswire.com is pleased to announce a stock highlight on Dana Resources (OTC.BB:DANR), Power3 Medical Products, Inc. (OTCBB:PWRM), NewMarket Technology, Inc. (Pinksheets:NWMT)

Dana Resources (OTC.BB:DANR), a US-based precious metals exploration and development company, is pleased to announce the initiation of the production program at its Collota gold deposit. Dana Resources currently owns and operates seven mining projects located in Peru’s most prolific mining regions.

About Dana Resources Dana Resources is a precious and base metals exploration company with offices in the United States and Peru. Dana’s management team possesses local knowledge, extensive international connections, a wealth of experience and technical expertise in mining, mining finance, exploration and production. Dana Resources has acquired a portfolio of gold, silver and other precious & base metal properties located in Peru’s most prolific mining regions. With Peru growing as a producer of gold, silver and other metals on the international market, Dana Resources is well

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

DrStockPick.com News Report!

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Appoints Medical Director

-Lourdes R. Bosquez, MD, PA Appointed New Medical Director for PWRM-

 

Wednesday August 26, 2009

************************************************************** Power3 Medical Products, Inc. Appoints Medical Director

Lourdes R. Bosquez, MD, PA Appointed New Medical Director for Power3 Medical Products, Inc.

Woodlands, TX, - (CRWENEWSWIRE - 08/26/09) Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), today announced that Lourdes R. Bosquez, MD, PA, was appointed Medical Director of the Company.

Power3 Medical Products, Inc., a biotechnology company with diagnostic products for Alzheimer’s disease, Parkinson’s disease, Breast Cancer and other diseases,

...

AZ-004 (Staccato loxapine) is a pre-NDA candidate for the treatment of acute agitation in patients with schizophrenia and/or bipolar disorder.  Management at Alexza Pharmaceuticals (ALXA) is focused on completing the necessary non-pivotal safety and supportive work, as well as the chemical and manufacturing scale-up, on AZ-004 in preparation of the planned NDA [new drug application] filing in early 2010. Besides the preparation that is being done for the AZ-004 NDA, management is focusing on partnering opportunities for the drug. There are currently no real effective treatment options for patients with schizophrenia or bipolar disorder with acute agitation. In most instances, anti-psychotic drugs are used with varying degrees of success. Care-givers are looking for three key attributes in a treatment options:  speed of onset, predictability of response and convenience and non-invasiveness of delivery. Injectable drugs provide rapid onset and predictability, but the invasiveness of an intramuscular injection during ...

Last week, Johnson & Johnson (JNJ) announced the marketing approval of Invega extended-release tablets either for solo use or in combination with mood stabilizers and antidepressants for treating schizoaffective disorder. The disorder results in symptoms similar to schizophrenia in addition to mania or depression.

On the same day, the US agency gave its nod of approval to Invega Sustenna -- a once-monthly, injectable version of Invega to treat schizophrenia in adults. It will be marketed in the US by Janssen, a unit of Johnson & Johnson.

Invega Sustenna has been developed using the proprietary technology NanoCrystal Technology, which is a registered trademark of Elan Pharma International Ltd, Ireland, a subsidiary of Elan Corp. plc (ELN). The FDA approved the drug on the basis of two international, randomized, double-blind placebo-controlled studies of schizoaffective disorder patients with acute symptoms.

Approximately, one percent of the world’s population suffers from schizophrenia, which prevents a person

...